UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 29, 2004
England and Wales
(State or other jurisdiction of incorporation)
| 0-29630 (Commission File Number) | 98-0359573 (IRS Employer Identification No.) |
Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code 44 1256 894 000
______________________________________________________________________
(Former name or former address, if changed since last report)
Item 7. Financial Statements and Exhibits
(c) Exhibits. The following exhibit is filed herewith:
99.1 Press release of Shire Pharmaceuticals Group plc dated April 29, 2004, reporting Shire’s financial results for the first quarter of 2004.
Item 12. Results of Operations and Financial Conditions
On April 29, 2004 Shire Pharmaceuticals Group plc issued a press release announcing its financial results for the first quarter of 2004. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SHIRE PHARMACEUTICALS GROUP PLC | ||
| By: | /s/ A C Russell | |
Dated: April 29, 2004
EXHIBIT INDEX
Number Description
99.1 Press release of Shire Pharmaceuticals Group plc dated April 29, 2004, reporting Shire’s financial results for the first quarter of 2004.
